Minocycline safety and tolerability in Huntington disease
- 10 August 2004
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (3) , 547-549
- https://doi.org/10.1212/01.wnl.0000133403.30559.ff
Abstract
Minocycline is an antibiotic with anti-inflammatory and antiapoptotic properties that prolongs survival in a transgenic Huntington disease (HD) mouse model. In a double-blind, randomized, placebo-controlled study of minocycline in 60 HD patients, the authors determined that over 8 weeks, minocycline at 100 and 200 mg/day was well tolerated and safe in HD patients. Tolerability and adverse event frequency were similar between treatment and placebo groups.Keywords
This publication has 8 references indexed in Scilit:
- Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's diseaseProceedings of the National Academy of Sciences, 2003
- Apoptosis and Caspases in Neurodegenerative DiseasesNew England Journal of Medicine, 2003
- Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington diseaseNature Medicine, 2000
- Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's diseaseNature, 1999
- Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine TractJournal of Biological Chemistry, 1998
- Unified Huntington's disease rating scale: Reliability and consistencyMovement Disorders, 1996
- Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?Trends in Neurosciences, 1993
- A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomesCell, 1993